Etomidate is a commonly used induction agent in the United States. Its use in sepsis has become a focus of discussion, particularly in recent years as the CORTICUS study showed that patients receiving etomidate had a 17% increased rate of adrenal suppression and increased risk of death at 28 days (40–45% vs. 30–32%). 59However, since that time, several prospective and retrospective studies have not shown a statistically significant increase in mortality with the use of etomidate. As such, there are no definitive data at this time preventing the use of etomidate in SS/SS. There are, however, advantages to other agents such as ketamine, which has drawn attention due to its sympathomimetic effects on heart rate, blood pressure,and cardiac output. Presently, the choice of induction agent is clinician-dependent.